edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: Chosa
Chosa Oncology (previously RhoVac) is a Danish biotech focused on the development of iCIP, a technology consisting of a cisplatin drug response predictor and a liposomal formulation of conventional cisplatin. iCIP has demonstrated encouraging clinical proof of concept from a Phase IIb study in breast cancer patients and Chosa is now looking for strategic partnerships to progress clinical development of the technology.
Chosa — 2 videos in collection
In this video we speak with Peter Buhl Jensen, CEO of CHOSA Oncology, and Claus Frisenberg, the company’s CFO. Chosa is a Scandinavian biotechnology company focused on the development of its proprietary drug response predictor (DRP). In the interview, Peter and Claus cover how the DRP helps stratify cancer patients who are most likely to respond to platinum chemotherapy, the data that Chosa has acquired to support its application in various cancer types, and the potential to use it in combination regimens with an immunotherapy partner. Peter and Claus also outline Chosa’s regulatory and commercial strategy, as well as key catalysts and milestones to watch out for over the next 12 months.
Get access to the very latest content matched to your personal investment style.